The demo realized both its Major endpoints, with semaglutide 2.4 mg demonstrating statistically considerable and excellent enhancements in liver fibrosis without any worsening of steatohepatitis, and resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH when compared with placebo.1Regimen monitoring of serum calciton